0HTC Stock Chart & Stats
$3.38
$0.00(0.00%)
At close: 4:00 PM EDT
$3.38
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3.38 - $15.99
Previous CloseN/A
Volume0.00
Average Volume (3M)39.00
Market Cap
$24.28M
Enterprise Value$2.20
Total Cash (Recent Filing)$15.77M
Total Debt (Recent Filing)$145.00K
Price to Earnings (P/E)―
Beta-0.72
Next Earnings
Nov 12, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.79
Shares Outstanding13,338,943
10 Day Avg. Volume117
30 Day Avg. Volume39
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.67Price Target Upside156.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
TTI-109 Phase 1 ValidationTTI-109’s human data support mechanism validation and a potentially more usable oral profile. Target engagement plus improved tolerability can improve the probability of advancing into broader inflammatory and proliferative disease studies, although efficacy is not yet established.
Defined Ulcerative Colitis StrategySelecting ulcerative colitis gives the pipeline a defined lead indication and targets a sizable underserved disease area. A tissue-targeted oral STAT3 approach could differentiate from single-pathway therapies, while the planned 2027 study creates a development path.
Low Current LeverageMinimal reported debt limits interest and repayment pressure while the company funds clinical development. The improved burn trend, if sustained, could extend capital efficiency, though it does not eliminate the need for external financing.
Bears Say
No Current Revenue BaseThe absence of revenue in 2025 and TTM, following a steep decline from 2022–2024, shows no commercial base is currently supporting operations. Persistent negative EBIT and a $26.1M TTM net loss leave results dependent on future clinical success.
Persistent Cash ConsumptionOperating and free cash flow remain negative, including about $25.0M TTM, so clinical programs consume cash rather than fund themselves. Continued reliance on external capital creates execution risk if financing becomes less available or costly.
Funding And Dilution RiskThe expanded ATM facility provides financing capacity but signals that ongoing development requires equity funding. Additional share issuance can dilute existing holders, while shrinking assets and prior negative equity indicate limited internal financial flexibility.
Tvardi Therapeutics News
0HTC FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest share price was $3.38 and its highest was $15.99 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $24.28M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 76 days.
How were Tvardi Therapeutics’s earnings last quarter?
Tvardi Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.704 by $0.014.
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Tvardi Therapeutics dividends here
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.56.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 13,338,943 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Tvardi Therapeutics reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.704. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in GB:0HTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
0HTC Stock 12 Month Forecast
Average Price Target
$8.67
▲(156.41% Upside)
Technical Analysis
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―